Literature DB >> 28256916

Long-term risk of reproductive cancer among Vietnamese women using the quinacrine hydrochloride pellet system vs. intrauterine devices or tubal ligation for contraception.

Judith K Jones1, Arlene Tave1, John C Pezzullo2, Sharon Kardia3, Jack Lippes4.   

Abstract

OBJECTIVES: To determine the long-term risk of reproductive tract cancer in women using the quinacrine hydrochloride pellet system of permanent contraception (QS) relative to the comparable risk in women using Copper T intrauterine device (IUD) or tubal ligation surgery (TL) for long-term or permanent contraception.
METHODS: This was a retrospective cohort study, conducted in the Northern Vietnamese provinces of Ha Nam, Nam Dinh, Ninh Binh and Thai Binh. Women who had their first QS procedure, last IUD insertion or TL between 1989 and 1996 were interviewed regarding post-procedure health outcomes, particularly reproductive tract cancers.
RESULTS: A 95% response rate resulted in 21,040 completed interviews. Reproductive cancer incidence rates were very low (5.77/100,000 women years of follow-up time; 95%CI = 3.72-8.94). No significant excess hazard of reproductive tract cancer was associated with QS.
CONCLUSIONS: No significant excess long-term risk of reproductive tract cancer was found after an average 16 years of follow-up among a large group of women using QS vs. IUD/TL for contraception.

Entities:  

Keywords:  Quinacrine; female; non-surgical permanent contraception; retrospective cohort study; survival analysis

Mesh:

Substances:

Year:  2017        PMID: 28256916     DOI: 10.1080/13625187.2017.1285880

Source DB:  PubMed          Journal:  Eur J Contracept Reprod Health Care        ISSN: 1362-5187            Impact factor:   1.848


  1 in total

1.  Calf Thymus DNA Exposed to Quinacrine at Physiological Temperatures and pH Acquires Immunogenicity: A Threat for Long Term Quinacrine Therapy.

Authors:  Kumari Suganthy Asha; Safia Habib; Shahid Ali Siddiqui; Asif Ali
Journal:  Indian J Clin Biochem       Date:  2021-10-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.